2024年度非小细胞肺癌放射治疗研究进展  

Research progress of radiotherapy for non-small cell lung cancer in 2024

作　　者：李加冉 袁双虎 Li Jiaran;Yuan Shuanghu(Department of Radiation Oncology,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,Anhui,China)

机构地区：[1]中国科学技术大学附属第一医院放疗科,安徽合肥230001

出　　处：《肿瘤综合治疗电子杂志》2025年第1期50-57,共8页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家自然科学基金面上项目(82473235,82073345)。

摘　　要：2024年度非小细胞肺癌(non-small cell lung cancer,NSCLC)放射治疗(简称放疗)领域取得了一系列进展,为NSCLC患者提供了更精准和个体化的治疗选择。在早期NSCLC中,立体定向体部放疗对不可手术患者疗效显著,而对于可切除患者放疗与手术各有优劣。局部晚期NSCLC的术后放疗、新辅助放疗及不可切除患者放疗各方面均有深入探索。术后放疗对特定N2期患者群体有益,新辅助放化疗联合免疫治疗的三联疗法显示出良好的疗效和安全性。对于不可切除局部晚期NSCLC患者,基于PACIFIC模式(同步放化疗后免疫巩固治疗)的研究持续深入,涵盖放疗剂量与分割方式的优化以及免疫治疗的联合应用等方面。此外,在驱动基因阳性NSCLC患者中,根治性放化疗后的靶向巩固治疗逐步形成一种新的治疗模式。在晚期NSCLC中,放疗联合免疫治疗及靶向治疗显示出了强大的协同效应,为更多患者带来持续的临床获益。本文旨在总结2024年度NSCLC放疗研究进展。In 2024,a series of progress has been made in radiation therapy for non-small cell lung cancer(NSCLC),offering more precise and personalized treatment options for patients.For early NSCLC,stereotactic body radiotherapy is effective for inoperable patients,while the effectiveness of radiotherapy compared to surgery for resectable cases remains uncertain.In locally advanced NSCLC,there has been substantial progress in postoperative radiotherapy,neoadjuvant radiotherapy,and radiotherapy for unresectable cases.Postoperative radiotherapy has proven beneficial for specific groups of patients with N2 disease.Additionally,neoadjuvant trimodal therapy combining radiotherapy,chemotherapy,and immunotherapy has shown promising efficacy and safety.For patients with unresectable locally advanced NSCLC,studies building upon the PACIFIC regimen(immune consolidation therapy after concurrent chemoradiotherapy)continue to evolve,focusing on optimizing radiotherapy doses and fractionation schedules as well as integrating immunotherapy.Among patients with driver mutations,targeted maintenance therapy following definitive chemoradiotherapy is shaping a new treatment paradigm.Furthermore,the combination of radiotherapy with immunotherapy and targeted therapy in advanced NSCLC has shown potent synergistic effects,bringing substantial clinical benefits to a broader range of patients.This paper aims to present the research progress in thefield of radiotherapy in NSCLC in 2024.

关 键 词：非小细胞肺癌 放射治疗 免疫治疗 靶向治疗 

分 类 号：R73[医药卫生—肿瘤]